An Illinois federal judge ordered Boehringer Ingelheim International GmbH (BII) last month to reimburse Plaintiffs for the offices they rent for European depositions in the multidistrict lit... Read more
Just 18 months after a multidistrict litigation (MDL) was formed, Boehringer Ingelheim International GmbH is now facing more than 2,000 lawsuits in the U.S. over severe bleeding and other in... Read more
An Illinois federal judge has ordered Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) to pay nearly $1 million as sanctions for discovery abuses in multidistrict litigation (MDL) involving... Read more
Our Mass Torts Section has been very busy over the past several months. Lawyers and staff personnel are currently involved in litigation involving a number of medications and devices. Some o... Read more
Boehringer Ingelheim Pharmaceuticals, Inc. has recalled a single manufacturing lot of Pradaxa® (dabigatran etexilate mesylate), 75mg 60 US, NDC 0597- 0149-54, lot 201900, Exp January 2015. P... Read more
When the U.S. Food and Drug Administration released the result of a Mini-Sentinel assessment of Pradaxa, the new-age anti-clotting agent that serves as an alternative to the 60-year-old stan... Read more
A new report suggests some doctors are concerned about Pradaxa side effects, which reportedly include an increased risk of death due to bleeding. Concerns have been raised that patients who... Read more
Approved by the FDA in October 2010, Pradaxa (Dabigatran) is marketed by Boehringer Ingelheim Pharmaceuticals, Inc., to reduce the risk of strokes and blood clots in people who have atrial f... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.